中和抗体市场报告：2031 年趋势、预测和竞争分析

全球中和抗体市场未来前景光明，医院和诊所、研究机构、诊断实验室和製药公司市场都存在机会。预计 2025 年至 2031 年期间全球中和抗体市场复合年增长率为 11.2%。这个市场的主要驱动因素是类风湿性关节炎、多发性硬化症和红斑性狼疮等自体免疫疾病的发生率不断上升，感染疾病病率不断上升，以及人们越来越意识到抗体疗法相对于传统疫苗和药物的益处。

• Lucintel 预测，在预测期内，治疗领域仍将是最大的应用领域。
• 在最终用途类别中，製药公司将继续成为最大的细分市场。
• 根据地区划分，由于主要参与者的存在和遍布全国的强大的医疗保健系统，预计北美将在预测期内继续成为最大的地区。

中和抗体市场的策略性成长机会

中和抗体市场的策略性成长受到其在各个治疗领域的应用的推动。公司看到了感染疾病、肿瘤学和个人化医疗领域的巨大成长机会，以扩大其市场占有率。

• 感染疾病治疗：感染疾病尤其是新冠肺炎的增多，为中和抗体创造了巨大的成长机会。公司正致力于快速核准和大规模生产抗体以满足全球需求。
• 肿瘤学：肿瘤学仍然是中和抗体和标靶治疗疗法的主要成长领域，这些疗法为难以治疗的癌症患者提供了有希望的治疗方法。能够选择性攻击癌细胞的抗体的发展是一个主要驱动力。
• 自体免疫疾病：中和抗体越来越多地被应用于治疗自体免疫疾病，提供标靶治疗，以最大限度地减少副作用并改善患者的治疗效果。
• 慢性疾病：中和抗体在糖尿病和心血管疾病等慢性疾病中的使用正在增加，为改善长期健康结果提供了新的治疗选择。
• 个人化医疗：个人化医疗的进步为开发针对个别患者基因特征的中和抗体创造了机会，从而提高了一系列疾病治疗的精准度和疗效。

这些策略性成长机会推动了创新并扩大了中和抗体在多个治疗领域的使用，为市场持续扩张奠定了基础。

中和抗体市场驱动因素与挑战

中和抗体市场受到技术进步、监管状况和经济状况等多种因素的影响。这些市场驱动因素和挑战将在塑造市场未来成长轨迹方面发挥关键作用。

推动中和抗体市场的因素包括：

• 对 COVID-19 治疗的需求不断增长：全球大流行刺激了对中和抗体的需求，特别是对 COVID-19 治疗的需求，从而导致研究增加和监管核准加快。
• 生物技术的进步：生物技术的不断进步使得更有效、更有针对性的中和抗体的开发成为可能，从而推动了市场的成长。
• 肿瘤学：中和抗体在癌症治疗中的广泛应用是一个主要驱动因素，良好的临床结果带来了新的核准和市场扩张。
• 政府支持和资金：政府正在增加对抗体研究的资助，特别是在感染疾病和肿瘤学领域，从而促进研发并加速市场成长。
• 合作伙伴关係：製药公司和研究机构之间的合作促进了新型抗体疗法的快速开发和商业化。

中和抗体市场面临的挑战如下：

• 开发成本高：开发中和抗体需要大量的研发和临床试验投入，这对中小企业来说是一个挑战。
• 监管障碍：生物製药复杂的监管环境可能会延迟产品核可，影响新型疗法的上市时间。
• 製造复杂性：生产中和抗体是一个复杂的过程，扩大生产规模是一项挑战，尤其是在新兴市场。

中和抗体市场受到技术进步、政府支持和对新型疗法的不断增长的需求的推动。然而，在市场充分发挥其潜力之前，需要解决高开发成本和监管障碍等挑战。

目录

第一章执行摘要

第 2 章全球中和抗体市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动因素与挑战

第 3 章 2019 年至 2031 年的市场趋势与预测分析

• 宏观经济趋势（2019-2024）与预测（2025-2031）
• 全球中和抗体市场趋势（2019-2024）及预测（2025-2031）
• 全球中和抗体市场（按目标病毒）
  • SARS-CoV-2
  • HIV
  • 流感
  • 伊波拉
  • 兹卡热
  • C型肝炎
• 全球中和抗体市场（以抗体类型划分）
  • 单株抗体
  • 多株抗体
• 全球中和抗体市场（按应用划分）
  • 治疗
  • 诊断
  • 研究与开发
  • 其他的
• 全球中和抗体市场（依最终用途划分）
  • 医院和诊所
  • 研究组织
  • 诊断实验室
  • 製药公司
  • 其他的

第 4 章 2019 年至 2031 年各地区的市场趋势与预测分析

• 全球中和抗体市场（按地区）
• 北美中和抗体市场
• 欧洲中和抗体市场
• 亚太地区中和抗体市场
• 其他地区的中和抗体市场

第五章 竞争分析

• 产品系列分析
• 业务整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球中和抗体市场成长机会（按目标病毒）
  • 全球中和抗体市场按抗体类型分類的成长机会
  • 全球中和抗体市场成长机会（按应用划分）
  • 全球中和抗体市场成长机会（依最终用途划分）
  • 全球中和抗体市场成长机会（按地区划分）
• 全球中和抗体市场的新趋势
• 战略分析
  • 新产品开发
  • 全球中和抗体市场产能扩大
  • 全球中和抗体市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

The future of the global neutralizing antibody market looks promising with opportunities in the hospital and clinic, research institute, diagnostic laboratory, and pharmaceutical company markets. The global neutralizing antibody market is expected to grow with a CAGR of 11.2% from 2025 to 2031. The major drivers for this market are the growing incidence of autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, and lupus, the rising prevalence of infectious diseases, and the increasing awareness of the benefits of antibody-based therapies compared to traditional vaccines and drugs.

• Lucintel forecasts that, within the application category, the therapeutic segment will remain the largest segment over the forecast period.
• Within the end-use category, pharmaceutical companies will remain the largest segment.
• In terms of regions, North America will remain the largest region over the forecast period due to the presence of major firms and a robust healthcare system across the country.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Neutralizing Antibody Market

The neutralizing antibody market is transforming due to technological innovations and a shift in healthcare priorities. These emerging trends are reshaping how companies develop and commercialize neutralizing antibody therapies globally.

• Increased Focus on COVID-19 Antibodies: With the global pandemic, there has been a surge in research for neutralizing antibodies targeting COVID-19. Companies are fast-tracking clinical trials and securing emergency use authorizations, making this a dominant trend in the market.
• Expansion in Oncology Treatments: Neutralizing antibodies are being increasingly utilized in oncology treatments. Companies are developing targeted therapies that attack specific cancer cells, offering more effective and less toxic treatment options.
• Personalized Medicine: The move toward personalized medicine is driving the development of antibodies tailored to individual patients' needs, particularly in cancer and autoimmune disorders. This trend enhances treatment efficacy and reduces side effects.
• Collaborations and Partnerships: The industry is seeing a rise in collaborations between biotech firms, pharmaceutical companies, and research institutions. These partnerships are speeding up innovation and enabling broader market access for new therapies.
• Technological Advancements in Biologics: Advancements in biologics manufacturing, including the use of cell-based and gene-editing technologies, are improving the efficiency and scalability of neutralizing antibody production, lowering costs, and boosting supply.

These trends are reshaping the neutralizing antibody market, with a focus on innovation, personalized treatments, and strategic collaborations, leading to more effective therapies and broader market penetration.

Recent Developments in the Neutralizing Antibody Market

The neutralizing antibody market has seen major advancements across various therapeutic areas, with key developments driving growth. Companies are focusing on innovation, partnerships, and regulatory milestones to capitalize on emerging opportunities in this fast-evolving market.

• COVID-19 Antibody Approvals: Several neutralizing antibodies have received emergency use authorizations for COVID-19 treatment, with major pharmaceutical companies launching new products that show efficacy in reducing viral loads.
• Oncology Innovations: Breakthroughs in neutralizing antibodies for oncology have been achieved, with new therapies targeting specific cancer cells, showing high effectiveness in clinical trials and receiving regulatory approvals in major markets.
• Collaborative Research Initiatives: There has been an increase in collaborative initiatives between biotech companies and academic institutions, particularly in the U.S. and Europe, aimed at accelerating antibody research for infectious diseases and cancers.
• Technological Advances in Manufacturing: Advances in biologics manufacturing have reduced production costs and improved scalability, making neutralizing antibodies more accessible and affordable for a wider range of treatments.
• Government Support for Biotechnology: Governments worldwide are increasing funding and support for biotechnology research, driving growth in the neutralizing antibody market as companies receive grants and tax incentives for R&D.

These developments are significantly impacting the neutralizing antibody market, fostering innovation, improving treatment outcomes, and enabling companies to capture new market opportunities globally.

Strategic Growth Opportunities for Neutralizing Antibody Market

Strategic growth in the neutralizing antibody market is being driven by its applications across various therapeutic areas. Companies are identifying key growth opportunities in infectious diseases, oncology, and personalized medicine, allowing them to expand their market presence.

• Infectious Disease Treatments: The rise of infectious diseases, particularly COVID-19, has created immense growth opportunities for neutralizing antibodies. Companies are focusing on fast-tracked approvals and large-scale production of antibodies to meet global demand.
• Oncology: Oncology remains a major growth area for neutralizing antibodies, with targeted therapies offering promising outcomes for patients with difficult-to-treat cancers. The development of antibodies that can selectively attack cancer cells is a key growth driver.
• Autoimmune Diseases: Neutralizing antibodies are increasingly being used in the treatment of autoimmune diseases, providing targeted therapies that minimize side effects and improve patient outcomes.
• Chronic Diseases: The use of neutralizing antibodies in chronic diseases, such as diabetes and cardiovascular conditions, is growing, offering new treatment options that improve long-term health outcomes.
• Personalized Medicine: Advances in personalized medicine are creating growth opportunities for neutralizing antibodies tailored to individual patients' genetic profiles, enhancing the precision and efficacy of treatments across various diseases.

These strategic growth opportunities are driving innovation and expanding the use of neutralizing antibodies across diverse therapeutic areas, positioning the market for continued expansion.

Neutralizing Antibody Market Driver and Challenges

The neutralizing antibody market is influenced by a variety of factors, including technological advancements, regulatory landscapes, and economic conditions. These drivers and challenges play a crucial role in shaping the market's future growth trajectory.

The factors responsible for driving the neutralizing antibody market include:

• Rising Demand for COVID-19 Therapies: The global pandemic has fueled demand for neutralizing antibodies, particularly for COVID-19 treatments, leading to increased research and rapid regulatory approvals.
• Advancements in Biotechnology: Continuous advancements in biotechnology are enabling the development of more effective and targeted neutralizing antibodies, driving market growth.
• Oncology Therapies: The expanding use of neutralizing antibodies in oncology is a major driver, with promising clinical results leading to new approvals and market expansion.
• Government Support and Funding: Governments are increasing funding for antibody research, particularly in infectious diseases and oncology, boosting R&D efforts and accelerating market growth.
• Collaborative Partnerships: Collaborations between pharmaceutical companies and research institutions are enabling faster development and commercialization of new antibody therapies.

Challenges in the neutralizing antibody market are:

• High Development Costs: The development of neutralizing antibodies requires significant investment in R&D and clinical trials, posing a challenge for smaller companies.
• Regulatory Hurdles: Navigating the complex regulatory landscape for biologics can slow down product approvals, impacting time-to-market for new therapies.
• Manufacturing Complexity: The production of neutralizing antibodies involves complex processes, making scaling up manufacturing a challenge, particularly in emerging markets.

The neutralizing antibody market is driven by technological advancements, government support, and rising demand for novel therapies. However, challenges such as high development costs and regulatory hurdles must be addressed for the market to reach its full potential.

List of Neutralizing Antibody Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies neutralizing antibody companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutralizing antibody companies profiled in this report include-

• Regeneron Pharmaceuticals
• Eli Lilly and Company
• AstraZeneca
• GlaxoSmithKline
• Sanofi
• Roche
• Novartis
• Merck
• Pfizer
• Johnson & Johnson

Neutralizing Antibody by Segment

The study includes a forecast for the global neutralizing antibody market by target virus, antibody type, application, end use, and region.

Neutralizing Antibody Market by Target Virus [Analysis by Value from 2019 to 2031]:

• SARS-CoV-2
• HIV
• Influenza
• Ebola
• Zika
• Hepatitis C

Neutralizing Antibody Market by Antibody Type [Analysis by Value from 2019 to 2031]:

• Monoclonal Antibodies
• Polyclonal Antibodies

Neutralizing Antibody Market by Application [Analysis by Value from 2019 to 2031]:

• Therapeutics
• Diagnostics
• Research and Development
• Others

Neutralizing Antibody Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals and Clinics
• Research Institutes
• Diagnostic Laboratories
• Pharmaceutical Companies
• Others

Neutralizing Antibody Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Neutralizing Antibody Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below are highlights of recent developments by major neutralizing antibody producers in key regions: the USA, China, India, Japan, and Germany.

• United States: In the U.S., recent advancements in neutralizing antibody research are driven by increased investment in COVID-19 therapies. The FDA has fast-tracked approvals for several monoclonal antibodies, further boosting the market as companies focus on cancer therapies and infectious disease treatments.
• China: In China, the neutralizing antibody market is witnessing rapid growth as local biotech companies invest in R&D and clinical trials for COVID-19 antibodies. Government support for innovation in biologics is accelerating the commercialization of neutralizing antibodies across multiple therapeutic areas.
• Germany: Germany's neutralizing antibody market is driven by collaborations between academic institutions and biotech companies. The country has made significant strides in developing antibodies for oncology and infectious diseases, with a focus on personalized medicine and targeted therapies.
• India: India's neutralizing antibody market is growing due to increased efforts in biotechnology and biopharma. The country is seeing a rise in clinical trials for COVID-19 therapies and a growing focus on antibody-based treatments for autoimmune and chronic diseases.
• Japan: Japan's neutralizing antibody market is experiencing growth driven by government initiatives to advance biotechnology and biopharmaceutical research. Major pharmaceutical companies are focusing on innovative monoclonal antibody treatments for cancer and other chronic conditions, contributing to market expansion.

Features of the Global Neutralizing Antibody Market

Market Size Estimates: Neutralizing antibody market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Neutralizing antibody market size by target virus, antibody type, application, end use, and region in terms of value ($B).

Regional Analysis: Neutralizing antibody market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different target virus, antibody type, application, end use, and regions for the neutralizing antibody market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutralizing antibody market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the neutralizing antibody market by target virus (SARS-CoV-2, HIV, influenza, Ebola, zika, and hepatitis C), antibody type (monoclonal antibodies and polyclonal antibodies), application (therapeutics, diagnostics, research and development, and others), end use (hospitals and clinics, research institutes, diagnostic laboratories, pharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutralizing Antibody Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Neutralizing Antibody Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Neutralizing Antibody Market by Target Virus
  • 3.3.1: SARS-CoV-2
  • 3.3.2: HIV
  • 3.3.3: Influenza
  • 3.3.4: Ebola
  • 3.3.5: Zika
  • 3.3.6: Hepatitis C
• 3.4: Global Neutralizing Antibody Market by Antibody Type
  • 3.4.1: Monoclonal Antibodies
  • 3.4.2: Polyclonal Antibodies
• 3.5: Global Neutralizing Antibody Market by Application
  • 3.5.1: Therapeutics
  • 3.5.2: Diagnostics
  • 3.5.3: Research and Development
  • 3.5.4: Others
• 3.6: Global Neutralizing Antibody Market by End Use
  • 3.6.1: Hospitals and Clinics
  • 3.6.2: Research Institutes
  • 3.6.3: Diagnostic Laboratories
  • 3.6.4: Pharmaceutical Companies
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Neutralizing Antibody Market by Region
• 4.2: North American Neutralizing Antibody Market
  • 4.2.1: North American Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.2.2: North American Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.3: European Neutralizing Antibody Market
  • 4.3.1: European Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.3.2: European Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.4: APAC Neutralizing Antibody Market
  • 4.4.1: APAC Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.4.2: APAC Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others
• 4.5: ROW Neutralizing Antibody Market
  • 4.5.1: ROW Neutralizing Antibody Market by Application: Therapeutics, Diagnostics, Research and Development, and Others
  • 4.5.2: ROW Neutralizing Antibody Market by End Use: Hospitals and Clinics, Research Institutes, Diagnostic Laboratories, Pharmaceutical Companies, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Neutralizing Antibody Market by Target Virus
  • 6.1.2: Growth Opportunities for the Global Neutralizing Antibody Market by Antibody Type
  • 6.1.3: Growth Opportunities for the Global Neutralizing Antibody Market by Application
  • 6.1.4: Growth Opportunities for the Global Neutralizing Antibody Market by End Use
  • 6.1.5: Growth Opportunities for the Global Neutralizing Antibody Market by Region
• 6.2: Emerging Trends in the Global Neutralizing Antibody Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Neutralizing Antibody Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutralizing Antibody Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Regeneron Pharmaceuticals
• 7.2: Eli Lilly and Company
• 7.3: AstraZeneca
• 7.4: GlaxoSmithKline
• 7.5: Sanofi
• 7.6: Roche
• 7.7: Novartis
• 7.8: Merck
• 7.9: Pfizer
• 7.10: Johnson & Johnson